Brief: Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
20/05/2025 13:11
May 20 (Reuters) - BridgeBio Pharma Inc BBIO.O: ACORAMIDIS REDUCED INCIDENCE OF ATRIAL FIBRILLATION EVENTS IN PATIENTS WITH ATTR-CM BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES ANNUAL CVH FREQUENCY DUE TO AF/AFL BY 43% BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES NEW-ONSET AF/AFL INCIDENCE BY 17% BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES ACM AND CVH EVENTS BY 42% AT MONTH 30 Source text: ID:nGNX1RJk6 Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels